Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics and BeiGene have started dosing patients in a trial combining an anti-PD-1 antibody with the novel targeted drug DKN-01 in patients with locally advanced gastric cancer.